Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.91M | 8.66M | 8.51M | 4.13M | 9.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.91M | 8.66M | 8.51M | 4.13M | 9.61M |
| Cost of Revenue | 21.50M | 25.28M | 22.51M | 25.14M | 23.16M |
| Gross Profit | -17.59M | -16.62M | -13.99M | -21.02M | -13.55M |
| SG&A Expenses | 6.78M | 6.22M | 6.99M | 6.81M | 7.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.28M | 31.50M | 29.50M | 31.95M | 30.24M |
| Operating Income | -24.37M | -22.84M | -20.99M | -27.82M | -20.62M |
| Income Before Tax | -22.49M | -20.63M | -19.86M | -24.94M | -24.61M |
| Income Tax Expenses | 34.00K | -234.00K | 44.00K | 98.00K | -1.21M |
| Earnings from Continuing Operations | -22.53M | -20.39M | -19.91M | -25.04M | -23.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.53M | -20.39M | -19.91M | -25.04M | -23.40M |
| EBIT | -24.37M | -22.84M | -20.99M | -27.82M | -20.62M |
| EBITDA | -23.07M | -21.52M | -19.65M | -26.46M | -19.16M |
| EPS Basic | -0.60 | -0.55 | -0.54 | -0.68 | -0.63 |
| Normalized Basic EPS | -0.38 | -0.35 | -0.31 | -0.42 | -0.29 |
| EPS Diluted | -0.60 | -0.55 | -0.54 | -0.68 | -0.63 |
| Normalized Diluted EPS | -0.38 | -0.35 | -0.31 | -0.42 | -0.29 |
| Average Basic Shares Outstanding | 37.48M | 37.35M | 37.16M | 37.02M | 37.31M |
| Average Diluted Shares Outstanding | 37.48M | 37.35M | 37.16M | 37.02M | 37.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |